Matinas BioPharma (MTNB) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company leveraging lipid nanocrystal (LNC) platform for drug delivery.

• Lead candidate MAT2203 (oral amphotericin B) targets invasive fungal infections, with Phase 3 trial planned pending partnership or capital raise.

• Internal pipeline development paused after an 80% workforce reduction in late 2024; focus shifted to strategic alternatives and partnerships.

• Maintains active FDA IND for MAT2203 and ongoing intellectual property prosecution.

Financial performance and metrics

• As of June 15, 2026, public float market value was $5,579,577, with 6,398,597 shares held by non-affiliates at $0.872 per share.

• No securities sold under General Instruction I.B.6 of Form S-3 in the prior 12 months.

• Auditors included a going concern explanatory paragraph in the latest financial statements.

Use of proceeds and capital allocation

• Net proceeds from securities sales intended for working capital and general corporate purposes.

• Specific use of proceeds for each offering to be detailed in the relevant prospectus supplement.